



Docket No. B189 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
THE PATENT COOPERATION TREATY

In re application of: Karpusas, et al.
International Serial No.: PCT/US96/10664
International Filing Date: 21 June 1996 Earliest priority date 22 June 1995
TITLE: Crystals of Fragments of CD40 Ligands And Their Use

COPY

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office as Express Mail Label No. EL118182859US in an Express Mail envelope addressed to: Box PCT, Assistant Commissioner for Patents, Washington, DC 20231 on the date shown.

4 November 1998
Date

Patricia Hofstetter
Patricia Hofstetter

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Transmittal Letter

Enclosed please find a Petition for Revival of An International Application For Patent Designating the U.S. Abandoned Unintentionally Under 37 CFR 1.137(b), Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371, and a copy of the published PCT application under Express Mail Label number EL118182859US.

The Commissioner is hereby authorized to charge our deposit account No. 02-2327 to cover the above fees including fees for Petition fee, and National filing fee including excess claims. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2327.

Sincerely,

Kerry Flynn

Kerry Flynn, Esq. (Reg. No. 33,693)
Attorney for Applicant
Biogen, Inc.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-3583

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371



B100

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.
PCT/US96/10664INTERNATIONAL FILING DATE
21 June 1996PRIORITY DATE CLAIMED
22 June 1995

TITLE OF INVENTION

Crystals of Fragments of CD40 Ligands and Their Use

APPLICANT(S) FOR DO/EO/US
BIOGEN, INC.

COPY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Petition for Revival on an International Application For Patent Designating the United States Abandoned
Unintentionally under 37 CFR 1.137(b)

**PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT
DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number (Optional)
B189- PCT

First named inventor: Karpusas

Application No.: PCT/US96/10664

Group Art Unit: Not yet known

Filed: 21 June 1996

Examiner: Not yet known

Title: Crystals of Fragments of CD40 Ligand and Their Use

Attention: International Division, Legal Staff
Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231



COPY

The above-identified application became abandoned as to the United States because the elements noted at 35 U.S.C. 371(c) were not filed prior to the expiration of the applicable time limit noted at 37 CFR 1.494(b) or (c) or 37 CFR 1.495(b) or (c). The date of abandonment is * (i.e., the day after the date on which the 35 U.S.C. 371(c) requirements were due; see 37 CFR 1.494(h) or 1.495(i)). * December 23, 1997

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper response
- (3) Terminal disclaimer with disclaimer fee – required for all applications filed before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

- ☐ Small entity - fee \$ (37 CFR 1.17(m))
- ☐ Small entity statement enclosed herewith.
- ☐ Small entity statement previously filed.
- ☒ Other than small entity - fee \$ 1320 (37 CFR 1.17(m))

2. Proper response

A. The proper response (the missing 35 U.S.C. 371(c) requirements) in the form of a Transmittal Letter to US/DEO con Filing Under 35 (identify type of response):

- ☐ has been filed previously on U.S.C. 371
- ☒ is enclosed herewith.

[Page 1 of 2]